Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer

BACKGROUND Prostate specific antigen (PSA) is widely used for prostate cancer screening but its levels are influenced by many non cancer‐related factors. The goal of the study is to estimate the effect of genetic variants on PSA levels. METHODS We evaluated the association of SNPs that were reported...

Full description

Saved in:
Bibliographic Details
Published inThe Prostate Vol. 69; no. 4; pp. 419 - 427
Main Authors Wiklund, Fredrik, Zheng, S. Lilly, Sun, Jielin, Adami, Hans-Olov, Lilja, Hans, Hsu, Fang-Chi, Stattin, Pär, Adolfsson, Jan, Cramer, Scott D., Duggan, David, Carpten, John D., Chang, Bao-Li, Isaacs, William B., Grönberg, Henrik, Xu, Jianfeng
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.03.2009
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BACKGROUND Prostate specific antigen (PSA) is widely used for prostate cancer screening but its levels are influenced by many non cancer‐related factors. The goal of the study is to estimate the effect of genetic variants on PSA levels. METHODS We evaluated the association of SNPs that were reported to be associated with prostate cancer risk in recent genome‐wide association studies with plasma PSA levels in a Swedish study population, including 1,722 control subjects without a diagnosis of prostate cancer. RESULTS Of the 16 SNPs analyzed in control subjects, significant associations with PSA levels (P ≤ 0.05) were found for six SNPs. These six SNPs had a cumulative effect on PSA levels; the mean PSA levels in men were almost twofold increased across increasing quintile of number of PSA associated alleles, P‐trend = 3.4 × 10−14. In this Swedish study population risk allele frequencies were similar among T1c case patients (cancer detected by elevated PSA levels alone) as compared to T2 and above prostate cancer case patients. CONCLUSIONS Results from this study may have two important clinical implications. The cumulative effect of six SNPs on PSA levels suggests genetic‐specific PSA cutoff values may be used to improve the discriminatory performance of this test for prostate cancer; and the dual associations of these SNPs with PSA levels and prostate cancer risk raise a concern that some of reported prostate cancer risk‐associated SNPs may be confounded by the prevalent use of PSA screening. Prostate 69:419–427, 2009. © 2008 Wiley‐Liss, Inc.
Bibliography:National Cancer Institute - No. CA105055 CA106523 CA95052 CA129684 P50-CA92629 SPORE
istex:E87F8F32ED5B92256971634904B88A89D64E2EA4
Department of Defense - No. PC051264
Swedish Research Council (Medicine) - No. 20095
ArticleID:PROS20908
Swedish Academy of Sciences (Vetenskapsrådet)
Fredrik Wiklund and S. Lilly Zheng contributed equally to this work.
Swedish Cancer Society - No. 3555
Swedish Cancer Society (Cancerfonden)
ark:/67375/WNG-HZC3ZBXP-C
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0270-4137
1097-0045
1097-0045
DOI:10.1002/pros.20908